Skip to main content
Top
Published in: Rheumatology International 1/2012

01-01-2012 | Original Article

Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case–control study from a single center

Authors: Melissa Padovan, Gabriella Castellino, Alessandra Bortoluzzi, Luisa Caniatti, Francesco Trotta, Marcello Govoni

Published in: Rheumatology International | Issue 1/2012

Login to get access

Abstract

To evaluate, by a retrospective cross-sectional case–control study from a single center, the distribution of a number of factors and comorbidities potentially related to central nervous system involvement in SLE Italian patients, a number of “generic” (i.e. not strictly SLE related) and “specific” (i.e. SLE related) risk factors were checked and their distribution analyzed in SLE patients with (NPSLE) and without (SLE) neuropsychiatric (NP) involvement. One hundred and fifty-three SLE patients with NP involvement observed from 1999 to 2008 and 247 SLE patients without NP manifestations, matched for sex, age and disease duration were included in the study. A neuropsychiatric (NP) event represented the heralding symptom of the disease in 40.5% of NPSLE. Headache, cerebrovascular events, mood disorders and seizures were the most frequent NP manifestations. NPSLE patients had a major cumulative number of the investigated factors than controls without NP involvement. Antiphospholipid antibodies (aPL), lupus anticoagulant (LA), Antiphospholipid antibodies syndrome (APS), Raynaud’s phenomenon, smoke, assumption of contraceptives and higher cumulative dose of glucocorticosteroids (GC) were significantly more commonly observed among NPSLE. APS and systemic arterial hypertension were more frequently detected among patients with focal NP manifestations, especially cerebrovascular events. aPL, LA, APS, Raynaud’s phenomenon, smoke, contraceptives intake and higher cumulative dose of GC did prove more frequently detected in NPSLE patients than in controls. In particular, overall, arterial hypertension should be regarded as a potential independent “risk factor” for focal involvement, especially for cerebrovascular events.
Literature
1.
go back to reference ACR ad hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology (1999) Arthritis Rheum 42:599–608 ACR ad hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology (1999) Arthritis Rheum 42:599–608
2.
go back to reference Unterman A, Nolte JES, Boaz M et al (2009) The prevalence of neuropsychiatric syndromes in sle: a metanalysis. 2009 annual scientific meeting of the American college of rheumatology, Philadelphia 16–21 October. Arthritis Rheum 60(suppl):S589 Unterman A, Nolte JES, Boaz M et al (2009) The prevalence of neuropsychiatric syndromes in sle: a metanalysis. 2009 annual scientific meeting of the American college of rheumatology, Philadelphia 16–21 October. Arthritis Rheum 60(suppl):S589
3.
go back to reference Hanly JG, Walsh NMG, Sangalang V (1992) Brain pathology in systemic lupus erythematosus. J Rheumatol 19:732–741PubMed Hanly JG, Walsh NMG, Sangalang V (1992) Brain pathology in systemic lupus erythematosus. J Rheumatol 19:732–741PubMed
4.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShone DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries JF, Masi AT, McShone DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
5.
go back to reference Castellino G, Padovan M, Bortoluzzi A, Borrelli M, Feggi L, Caniatti ML, Trotta F, Govoni M (2008) Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology (Oxford) 47:319–323CrossRef Castellino G, Padovan M, Bortoluzzi A, Borrelli M, Feggi L, Caniatti ML, Trotta F, Govoni M (2008) Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology (Oxford) 47:319–323CrossRef
6.
go back to reference Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure (JNC-V1) (1997) Sixth report. Arch Intern Med. 157:2413–2446 Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure (JNC-V1) (1997) Sixth report. Arch Intern Med. 157:2413–2446
7.
go back to reference World Health Organization (1997) Obesity: preventing and managing the global epidemic. World health Organization Geneva World Health Organization (1997) Obesity: preventing and managing the global epidemic. World health Organization Geneva
8.
go back to reference The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197
9.
go back to reference Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (2001) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (2001) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497
10.
go back to reference Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definitive antiphospholipid syndrome. Arthritis Rheum 42:1309–1311PubMedCrossRef Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al (1999) International consensus statement on preliminary classification criteria for definitive antiphospholipid syndrome. Arthritis Rheum 42:1309–1311PubMedCrossRef
11.
go back to reference Horbach DA, Oort E, Donders RC, Derksen RH, de Groot PG (1996) Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus (comparison between different assays for the detection of antiphospholipid antibodies). Thromb Haemost 76:916–924PubMed Horbach DA, Oort E, Donders RC, Derksen RH, de Groot PG (1996) Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus (comparison between different assays for the detection of antiphospholipid antibodies). Thromb Haemost 76:916–924PubMed
12.
go back to reference Karassa FB, Ioannidis JPA, Touloumi G, Boki KA, Moutsopoulos HM (2000) Risk factors for central nervous system involvement in systemic lupus erythematosus. Q J Med 93:169–174CrossRef Karassa FB, Ioannidis JPA, Touloumi G, Boki KA, Moutsopoulos HM (2000) Risk factors for central nervous system involvement in systemic lupus erythematosus. Q J Med 93:169–174CrossRef
13.
go back to reference Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HM (1993) Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 2:303–312PubMedCrossRef Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HM (1993) Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 2:303–312PubMedCrossRef
14.
go back to reference West SG, Emlen W, Wener MH, Kotzin BL (1995) Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 99:155–163CrossRef West SG, Emlen W, Wener MH, Kotzin BL (1995) Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 99:155–163CrossRef
15.
go back to reference Toubi E, Khamashta MA, Panarra A, Hughes GR (1995) Association of antiphospholipid antibody with central nervous system disease in systemic lupus erythematosus. Am J Med 99:243–248CrossRef Toubi E, Khamashta MA, Panarra A, Hughes GR (1995) Association of antiphospholipid antibody with central nervous system disease in systemic lupus erythematosus. Am J Med 99:243–248CrossRef
16.
go back to reference Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992PubMed Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992PubMed
17.
go back to reference Brey RL, Holliday SL, Saklad AR et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58:1214–1220PubMed Brey RL, Holliday SL, Saklad AR et al (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58:1214–1220PubMed
19.
go back to reference Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR (2003) Central nervous system involvement in the antiphospholipid antibodies syndrome. Rheumatology 42:200–213PubMedCrossRef Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR (2003) Central nervous system involvement in the antiphospholipid antibodies syndrome. Rheumatology 42:200–213PubMedCrossRef
20.
go back to reference Trotta F, Dovigo L, Govoni M et al (1997) Neuropsychiatric involvement in systemic lupus erythematosus. A clinical and instrumental study in 116 North Italian Patients. Eur J Intern Med 8:95–103 Trotta F, Dovigo L, Govoni M et al (1997) Neuropsychiatric involvement in systemic lupus erythematosus. A clinical and instrumental study in 116 North Italian Patients. Eur J Intern Med 8:95–103
21.
go back to reference Karassa F, Ioannidis J, Boki K et al (2000) Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 109:628–634PubMedCrossRef Karassa F, Ioannidis J, Boki K et al (2000) Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 109:628–634PubMedCrossRef
22.
go back to reference Mikdashi J, Handwerger B (2004) Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology 43:1555–1560PubMedCrossRef Mikdashi J, Handwerger B (2004) Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology 43:1555–1560PubMedCrossRef
23.
go back to reference Sergent JS, Lockshin MD, Klempner MS, Lypsky BA (1975) Central nervous system disease in SLE: therapy and prognosis. Am J Med 58:644–654PubMedCrossRef Sergent JS, Lockshin MD, Klempner MS, Lypsky BA (1975) Central nervous system disease in SLE: therapy and prognosis. Am J Med 58:644–654PubMedCrossRef
24.
go back to reference Sibley JT, Olszynsky WP, Decoteau WE, Sundaram MB (1992) The incidence and prognosis of central nervous system in SLE. J Rheumatol 19:47–52PubMed Sibley JT, Olszynsky WP, Decoteau WE, Sundaram MB (1992) The incidence and prognosis of central nervous system in SLE. J Rheumatol 19:47–52PubMed
25.
go back to reference Brunner HI, Silverman ED, To T et al (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436–444CrossRef Brunner HI, Silverman ED, To T et al (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 46:436–444CrossRef
26.
go back to reference Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB (1976) Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 55:323–339PubMedCrossRef Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB (1976) Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 55:323–339PubMedCrossRef
27.
go back to reference Yee CS, Hussein H, Skan J, Skan J, Bowman S, Situayake D, Gordon C (2003) Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 42:276–279PubMedCrossRef Yee CS, Hussein H, Skan J, Skan J, Bowman S, Situayake D, Gordon C (2003) Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 42:276–279PubMedCrossRef
28.
go back to reference Schiffer LE, Hussain N, Wang X, Huang W, Sinha J, Ramanujam M, Davidson A (2002) Lowering anti-dsDNA antibodies-what’s new? Lupus 11:885–894PubMedCrossRef Schiffer LE, Hussain N, Wang X, Huang W, Sinha J, Ramanujam M, Davidson A (2002) Lowering anti-dsDNA antibodies-what’s new? Lupus 11:885–894PubMedCrossRef
29.
go back to reference Tektonidou MG, Ioannidis JPA, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM (2000) Prognostic factors and clustering of serious clinical outcomes in antiphospholipid antibodies syndrome. Q J Med 93:523–530CrossRef Tektonidou MG, Ioannidis JPA, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM (2000) Prognostic factors and clustering of serious clinical outcomes in antiphospholipid antibodies syndrome. Q J Med 93:523–530CrossRef
30.
go back to reference McLaurin EY, Holliday SL, Williams P, Brey RL (2005) Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64:297–303PubMedCrossRef McLaurin EY, Holliday SL, Williams P, Brey RL (2005) Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64:297–303PubMedCrossRef
31.
go back to reference Tomietto P, Annese V, D’Agostini S, Venturini P, La Torre G, De Vita S, Ferraccioli GF (2007) General and specific factor associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 57:1461–1472PubMedCrossRef Tomietto P, Annese V, D’Agostini S, Venturini P, La Torre G, De Vita S, Ferraccioli GF (2007) General and specific factor associated with severity of cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 57:1461–1472PubMedCrossRef
32.
go back to reference Mikdashi J, Krumholz A, Handwerger B (2005) Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 64:2102–2107PubMedCrossRef Mikdashi J, Krumholz A, Handwerger B (2005) Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 64:2102–2107PubMedCrossRef
33.
go back to reference McNicholl M, Glynn D, Mongey AB, Hutchinson M, Bresnihan B (1994) A prospective study of neurophysiologic, neurologic and immunologic abnormalities in systemic lupus erythematosus. J Rheumatol 21:1061–1066PubMed McNicholl M, Glynn D, Mongey AB, Hutchinson M, Bresnihan B (1994) A prospective study of neurophysiologic, neurologic and immunologic abnormalities in systemic lupus erythematosus. J Rheumatol 21:1061–1066PubMed
34.
go back to reference Ferraccioli G, Di Poi E, Di Gregorio F, Giacomuzzi F, Guerra U (1999) Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud’s syndrome. Lancet 354:2135–2136PubMedCrossRef Ferraccioli G, Di Poi E, Di Gregorio F, Giacomuzzi F, Guerra U (1999) Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud’s syndrome. Lancet 354:2135–2136PubMedCrossRef
35.
go back to reference Mathieu A, Sanna G, Passiu G, Cauli A, Piga M (2000) Raynaud’s syndrome in systemic lupus erythematosus. Lancet 355:1102–1103PubMedCrossRef Mathieu A, Sanna G, Passiu G, Cauli A, Piga M (2000) Raynaud’s syndrome in systemic lupus erythematosus. Lancet 355:1102–1103PubMedCrossRef
36.
go back to reference Annese V, Tomietto P, Venturini P, D’Agostini S, Ferraccioli GF (2006) Migraine in SLE: role of antiphospholipid antibodies and Raynaud’s phenomenon. Reumatismo 58:50–58PubMed Annese V, Tomietto P, Venturini P, D’Agostini S, Ferraccioli GF (2006) Migraine in SLE: role of antiphospholipid antibodies and Raynaud’s phenomenon. Reumatismo 58:50–58PubMed
37.
go back to reference Shoenfeld Y (2007) To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 28:165–169PubMedCrossRef Shoenfeld Y (2007) To smell autoimmunity: anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 28:165–169PubMedCrossRef
38.
go back to reference Meroni PL, Shoenfeld Y (2008) Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. Autoimmun Rev 7:585–587PubMedCrossRef Meroni PL, Shoenfeld Y (2008) Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. Autoimmun Rev 7:585–587PubMedCrossRef
39.
go back to reference Briani C, Lucchetta M, Ghirardello A, Toffanina E, Zampieri S, Ruggero S, Scarlato M, Quattrini A, Bassi N, Ermani M, Battistini L, Doria A (2009) Neurolupus is associated with anti-ribosomal P protein antibodies: an inception color study. J Autoimmun 32:79–84PubMedCrossRef Briani C, Lucchetta M, Ghirardello A, Toffanina E, Zampieri S, Ruggero S, Scarlato M, Quattrini A, Bassi N, Ermani M, Battistini L, Doria A (2009) Neurolupus is associated with anti-ribosomal P protein antibodies: an inception color study. J Autoimmun 32:79–84PubMedCrossRef
40.
go back to reference Katzav A, Ben-Ziv T, Chapman J, Blank M, Reichlin M, Shoenfeld Y (2008) Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). J Autoimmun 31:393–398PubMedCrossRef Katzav A, Ben-Ziv T, Chapman J, Blank M, Reichlin M, Shoenfeld Y (2008) Anti-P ribosomal antibodies induce defect in smell capability in a model of CNS-SLE (depression). J Autoimmun 31:393–398PubMedCrossRef
Metadata
Title
Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case–control study from a single center
Authors
Melissa Padovan
Gabriella Castellino
Alessandra Bortoluzzi
Luisa Caniatti
Francesco Trotta
Marcello Govoni
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 1/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1565-4

Other articles of this Issue 1/2012

Rheumatology International 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.